TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05097560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: HFNC provides humidified, heated, oxygen-enriched air at constant concentration with a flow up to 60L/min through a nasal cannula. It washouts the anatomical dead space and decreases the work of breathing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi mask
Description: VM is commonly used by COPD patients during exercise training.
Study: NCT05776589

Intervention type: DEVICE
Intervention: The mechanical ventilation mode
Description: Changing the mechanical ventilation mode

Intervention type: DEVICE
Intervention: The mechanical ventilation mode
Description: Changing the mechanical ventilation mode
Study: NCT05760833

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: Ablation of either the pulmonary veins or the atrioventricular node

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: Ablation of either the pulmonary veins or the atrioventricular node
Study: NCT04802291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HomeStyles-2: Obesity Prevention Program for Families with Children in Middle Childhood
Description: Comparison of 2 educational interventions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HomeStyles-2: Obesity Prevention Program for Families with Children in Middle Childhood
Description: Comparison of 2 educational interventions
Study: NCT05279443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga-based exercises therapy
Description: Accompanied by a certified yoga instructor, and under the supervision of an PMR specialist and a Sports Medicine specialist, YBEs were administered to our patients included in the study for 8 weeks, 2 sessions a week, and with sessions of 60 minutes, using personal mats and equipment in a 2475 m3 (18mx25mx5.5m) gym area that belonged to our hospital, in the form of group therapy for 5 (five) people and in accordance with the social distancing rules. The exercises program was applied as a exercise program consisting of physical postures (asana) to improve the body's muscle strength and flexibility, breathing exercises (pranayama) to increase respiratory function, and relaxation and meditation (dhyana) techniques.
Study: NCT05125757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle modification
Description: for 12 week, the patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual lifestyle
Description: the patients will receive the usual immuno-modulating therapy with continued usual diet and activities
Study: NCT06229197

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Billroth II reconstruction
Description: Billroth II reconstruction, in which a loop of jejunum is mobilized and anastomosed to the gastric remnant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Billroth II reconstruction
Description: Billroth II reconstruction, in which a loop of jejunum is mobilized and anastomosed to the gastric remnant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Braun Anastomosis
Description: This is an additional surgical connection (anastomosis) created between two parts of the small intestine, specifically between the afferent (incoming) and efferent (outgoing) limbs of the jejunum near the gastrojejunostomy (the new connection between the stomach and small intestine created during a Billroth II procedure).
Study: NCT05578456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone and Aspirin
Description: prednisone 10 mg and aspirin 75-100mg per day per os

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 2 starch tablets per day per os
Study: NCT06450795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participants in both groups will then receive PTKE treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists.
Description: HIFEM treatment for 6 weeks, 2 days a week for 28 minutes. The evaluations will be repeated at the end of the treatment.
Study: NCT06030804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A loading dose of dexmedetomidine (0.6 μg/kg) will be administered over 10-15 minutes before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery. Patient-controlled dexmedetomidine supplemented sufentanil analgesia will be provided after surgery: the formula contains a mixture of sufentanil (1.25 μg/ml) and dexmedetomidine (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume-matched normal saline will be administered in the same rate and volume for the same duration as in the dexmedetomidine group during anesthesia. Patient-controlled sufentanil analgesia will be provided after surgery: the formula contains sufentanil (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
Study: NCT05490511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus single dose
Description: 5 mg once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus single dose
Description: 5 mg once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus single dose
Description: 5 mg once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus single dose
Description: 5 mg once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidiolex single dose
Description: Epidiolex 5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidiolex single dose
Description: Epidiolex 5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidiolex single dose
Description: Epidiolex 5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidiolex single dose
Description: Epidiolex 5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidiolex steady-state and tacrolimus single dose
Description: Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidiolex steady-state and tacrolimus single dose
Description: Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidiolex steady-state and tacrolimus single dose
Description: Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidiolex steady-state and tacrolimus single dose
Description: Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
Study: NCT04832789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venovenous ECMO
Description: Venovenous ECMO
Study: NCT05906472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeds continued
Description: Enteral feeds are continued up until time of surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Feeds held
Description: Enteral feeds are stopped 6 or more hours before surgery
Study: NCT05337982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Downhill Eccentric Treadmill Training with Electrical Stimulation
Description: Participants will walk on a treadmill with a downward incline with support from a harness and assistance from trainers as needed. Participants will also simultaneously receive stimulation to their muscles including their trunk and legs. Each session will include 20 minutes of walking divided into 5 minute bouts with 5 minute rest breaks in between for 3 sessions per week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Downhill Eccentric Treadmill Training with Electrical Stimulation
Description: Participants will walk on a treadmill with a downward incline with support from a harness and assistance from trainers as needed. Participants will also simultaneously receive stimulation to their muscles including their trunk and legs. Each session will include 20 minutes of walking divided into 5 minute bouts with 5 minute rest breaks in between for 3 sessions per week for 12 weeks.
Study: NCT06405438

Intervention type: OTHER
Intervention: No intervention
Description: No intervention.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention.
Study: NCT04152668

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium curette.
Description: Implant debridement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titanium curette.
Description: Implant debridement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic
Description: Implant debridement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonic
Description: Implant debridement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air-polishing
Description: Implant debridement and polishing.
Study: NCT05880160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phased withdrawal of heart failure medications
Description: As per arm/group description
Study: NCT04856969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: First stage: ATB-1011 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: First stage: ATB-1011 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: First stage: ATB-1012 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: First stage: ATB-1012 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
Study: NCT05799911

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrogen rich water
Description: Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tap water with molecular hydrogen concentration 0.0 ppm.
Study: NCT04876404

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/MR Imaging
Description: The hybrid PET/MR scanner can provide information on brain activity during various motor and cognitive tasks.

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/MR Imaging
Description: The hybrid PET/MR scanner can provide information on brain activity during various motor and cognitive tasks.
Study: NCT06444854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early chest tube removal
Description: Chest tube removal
Study: NCT06405607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 30 mg single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.75 mg/kg weight-based single dose
Study: NCT05824663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM1020
Description: Intravenous (IV) Administrations on Days 1 of each 21-day treatment cycle.
Study: NCT05230446

Intervention type: DEVICE
Group type: OTHER
Intervention: PCI with OCT guidance
Description: Procedure will be optimize using pre-and post-stent OCT imaging, to improve the accuracy of stent placement and reduce geographic miss, but also to prevent malapposition of the stent and to discover dissections.
Study: NCT05237505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bi-level positive pressure non invasive ventilation
Description: Participants randomized to the bi-level arm will be provided with an auto bi-level device that automatically delivers the required pressure. The settings in the auto bi-level will be minimum EPAP of 4 cmH2O, maximum IPAP of 24 cmH2O, and a range of pressure support between 6-10 cmH2O. For those participants who have been randomized to the bi-level group but have not successfully acclimated to the device with the automatic bi-level settings, we will conduct an in-lab titration of the bi-level therapy during the optional Overnight visit 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Description: The dose of nocturnal oxygen in all participants in the oxygen therapy arm will be 2 liters/minute. Patients with daytime hypoxemia, measured as sustained desaturations below 89% during wake time and/or arterial blood PO2 ≤ 55 mmHg, will be excluded from this study (as specified in the exclusion criteria) for ethical reasons since withholding oxygen in hypoxemic patients would be at odds with standard of care.
Study: NCT06203392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate ketogenic diet
Description: Very low carbohydrate ketogenic diet provided for six weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: Mediterranean diet provided for six weeks
Study: NCT05306665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT intervention
Description: One day in person workshop + telephone booster
Study: NCT05096273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReACT
Description: ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReACT
Description: ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ReACT
Description: ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReACT
Description: ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations
Study: NCT05464940

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous caffeine
Description: Group assigned to receive caffeine will receive intravenous(IV) caffeine and sodium benzoate infusion starting at 250-500 mg.~This method will use an automated algorithm that adjusts the flow of the infusion depending on the individual's sex and weight and then in a serial fashion in response to blood caffeine measurements. Serial blood caffeine measurements at pre-determined intervals according to the algorithm will be until a steady state is obtained.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Masked Placebo
Description: The patients assigned to the masked placebo will receive 5% dextrose in 0.45% saline using the same infusion protocol for a random length of time that was within 1 standard deviation(SD) of the mean time to achieve a steady state using the caffeine protocol (17+4 min).~To maintain blinding, caffeine blood concentration measurements that will be randomly generated within 2 SDs of the predicted values calculated by the algorithm will be used and verbally communicated for placebo infusions.
Study: NCT05310123

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AC-11
Description: 6-months of treatment with AC-11
Study: NCT05937399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention video
Description: This intervention is an integrated health video provides individual (smoking) and environmental risk communication on intention to obtain lung cancer screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control video
Description: This intervention is an integrated health video provides individual (smoking) risk communication on intention to obtain lung cancer screening.
Study: NCT04638530

Intervention type: OTHER
Group type: OTHER
Intervention: Education on breaking bad news to family members remotely
Description: Participants will receive a combination of surveys, pre- and post-tests, lectures and didactics to increase their awareness of techniques to communicate difficult topics with patients remotely as well as skill building exercises.
Study: NCT04709835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: Results from Arm AT-527 500 mg determined the dose and regimen to be used for AT-527 1100 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: Results from Arm AT-527 500 mg determined the dose and regimen to be used for AT-527 1100 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The dose and regimen of the placebo will match that of the respective AT-527 comparator arm.
Study: NCT05700370

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MyProstateScore
Description: MyProstateScore is a urine-based biomarker test used to predict the risk of clinically significant prostate cancer
Study: NCT05475886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4
Description: An initial infusion dose of 500 ml 6% Hydroxyethyl starch (130/0.4) coload simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 100 ml according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT06132932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX390
Description: Participants will receive WX390 1.1 mg tablet orally once a day for a continuous 28-day cycle.
Study: NCT05682326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be administered up to Week 52.
Study: NCT05965076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glycine Perio Flow
Description: Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss and glycine perio-flow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glycine Perio Flow
Description: Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss and glycine perio-flow.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Angled Toothbrush
Description: Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and an angled toothbrush.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Angled Toothbrush
Description: Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and an angled toothbrush.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Professional Oral Hygiene
Description: Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Professional Oral Hygiene
Description: Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Domiciliary Oral Hygiene
Description: Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and a standard toothbrush.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Domiciliary Oral Hygiene
Description: Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and a standard toothbrush.
Study: NCT03702062

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6 Minute Walk Test Smart phone Application
Description: The intervention requests participants to user the smart phone application at prescribed frequencies during the follow-up period.
Study: NCT05153603

Intervention type: DRUG
Intervention: Olaparib mono-maintenance therapy
Description: Olaparib mono-maintenance therapy in patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III-IV) ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer is defined as drug exposure. At least one dose of olaparib tablets monotherapy as maintenance therapy will be required.
Study: NCT05823649

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Early feeding/intervention group
Description: The patients will be given orally 5 to 10 ml of warm water as first feeding. If there will be no problem of swallowing and other clinical complication, they will be further provided 20 ml of water after 10 minutes. If further patients do not suffer from nausea, vomiting and other discomfort, 100 ml clear fluid or less than it will be provided as based on the protocol followed by the study. We will use oral rehydration solution (ORS) as clear fluid.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early feeding/intervention group
Description: The patients will be given orally 5 to 10 ml of warm water as first feeding. If there will be no problem of swallowing and other clinical complication, they will be further provided 20 ml of water after 10 minutes. If further patients do not suffer from nausea, vomiting and other discomfort, 100 ml clear fluid or less than it will be provided as based on the protocol followed by the study. We will use oral rehydration solution (ORS) as clear fluid.
Study: NCT06146140

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral herbal supplement
Description: Take one capsule daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo supplement
Description: Take one capsule daily
Study: NCT05742789

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor

Intervention type: DRUG
Group type: OTHER
Intervention: Isoflurane
Description: В качестве анестетика использовали изофлуран - 1,1-1,2 MAC.

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: в качестве анестетика использовали севофлуран в дозе - 1,7-1,9 ПДК.
Study: NCT05120128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acuvue® Oasys 1-Day
Description: TEST Lens